In Europe skin melanoma (SM) survival has increased over time but differences between countries and areas of Europe remain.
Introduction
Skin melanoma (SM) incidence has increased sharply in most Western-type countries over the last decades; a trend that continues [1] . In 2012, SM ranked seventh among the most frequently diagnosed cancers in the European Union, 3.2% of all new cancers (all ages, both sexes). [2] The main known modifiable risk factor for SM is intermittent ultraviolet radiation exposure (UV). Therefore, the rise in incidence has been presumably driven by increased leisure exposure to UV radiation from sun and indoor tanning [3] .
Mortality rates are still increasing in many European countries (e.g. Ireland, Sweden, Netherlands, etc.) [2, 4] and they are nearly stable in others (e.g. Austria, Denmark, Croatia, Czech Republic, etc.) [2] .
According to previous EUROCARE studies, SM relative survival (RS) has increased over time [5] ;
SM ranks fourth among cancers with the best survival in Europe [6] .
However, survival varies markedly between and within European regions with only a slight decrease in geographical differences seen over time [5] . Survival also varies across age groups and between sexes.
The main prognostic factor for SM is stage at diagnosis (Breslow thickness) [7] and prompt and appropriate treatment. Therefore, in many countries a lot of effort is put in early diagnosis.
However, improvements in survival do not necessarily reduce mortality [8] . In fact, overdiagnosis and lead time bias affect survival without preventing deaths. Therefore, differences and changes in survival must be interpreted with caution.
The aim of the present EUROCARE-5 study is to provide updated data on SM RS, focusing on differences still present across European countries.
Materials and methods
We considered all adult patients (15 years and over) diagnosed in 2000-2007, with one or multiple invasive SM, which was defined by topography (C44.0-C44.9) and morphology (8720-8790) codes, according to the International Classification of Diseases for Oncology, (ICDO-3) [9] .
Overall, 241,485 cases from 29 countries (86 cancer registries [CRs]), divided into five European regions (Ireland and UK [Ireland/UK], Northern, Central, Southern and Eastern Europe), and followed up to the end of 2008 were included in the analyses.
We estimated the age-specific (15-44, 45-54, 55-64, 65-74, and 75+ years) and age-standardised 1year, 5-year and 5-year relative survival conditional to surviving 1 year after diagnosis.
We also presented the 5-year RS for different morphology and topography subgroups. In particular, we considered 5 morphology subgroups: superficial spreading (SSM, ICDO-3 code 8743), lentigo malignant (8742), nodular melanoma (8721), other specified types (8722-3, 8730, 8740-1, 8744-6, 8761, 8770-4, 8780) and not otherwise specified (NOS, 8720) SM; and 4 topography groups: head and neck (C44.0-C44.4), trunk (C44.5), limbs (C44.6-C44.7), overlapping and not specified sites (C44.8, C44.9).
Age-standardised incidence rates were also computed.
We also analysed trends in 5-year RS over 1999 5-year RS over -2001 5-year RS over , 2002 5-year RS over -2004 5-year RS over , and 2005 5-year RS over -2007 , involving 213,101 cases from the 65 CRs with complete incidence data from at least 1996 to 2006, with the exception of 16 CRs from France and Spain with data from 1995 to 2004.
Statistical methods
Data collection, quality checks process and statistical methods of the EUROCARE project were described elsewhere in this monograph [10] . In brief, RS for cases diagnosed in 2000-2007 was estimated by the complete cohort approach [11] and for time trends analyses the period approach [10.12] was applied. The Z-test [10] was used to compare survival estimates over the study period.
European survival estimates derived from the cohort analyses were country-weighted; whereas estimates in the trend analysis were area-weighted [10] .
Both age-specific and age-standardised [13] RS were obtained by using the Ederer II method for expected survival [14] , whereas incidence rates were age-standardised on the European standard population.
The Pearson's correlation coefficient [15] was computed between age-standardised incidence rates and age-standardised five-year RS for the period 2000-2007, by European region.
Finally, only the 51 out of 86 CRs with adequate morphology completeness (i.e. proportion of NOS SM < 30%) were included in the survival analyses for cases diagnosed in 2000-2007.
Results
The EUROCARE-5 database collected 243,417 SM diagnosed in 2000-2007 (Table 1) . Cases with major errors, known only from death certificate (DCO), or known from autopsy alone were excluded from the survival analyses. The proportion of major errors was 0% or negligible for the majority of the registries but 5% in Cracow (Poland). Moreover, the proportions of DCO and autopsy cases were, respectively, low (0.4%; range 0.0%-2.7%) or negligible (0.04%; range 0.0%-0.5%). After exclusions, 241,485 cases were included in the analyses. The proportion of microscopically verified cases was 98.5% (range 87.5%-100%).
Overall Europe, 15.4% of analysed SM were located on the head and neck (range 12.9%, Southern where almost all countries had low survival with the exception of Czech Republic (83.4%).
One-year RS was 95.1%, with the same -but less evident -ranking across countries than 5-year RS, 97.4% in Northern and 91.5% in Eastern Europe.
Patients who survived one year since diagnosis had a slightly better 5-year RS than those at the time of diagnosis (87.5% vs. 83.2%, European average). This improvement was quite small and homogeneous in Northern, Central Europe and Ireland and UK (around +3 percentage points) while it was higher in Southern (+4.8%) and Eastern (+6.9%) Europe.
The correlation coefficient between age-standardised survival and incidence rate was high (0.7), i.e. high incidence often coincided with high survival.
Overall Europe, RS was significantly higher in women than in men: the absolute difference in RS between women and men was +2.2% at 1 year after diagnosis, +5.9% at 3 years and +7.4% at five years ( Figure 1 ). Same results were evident for all age groups ( Figure 1 ) and each European region.
Differences in 5-year RS between sexes were quite stable across Europe, ranging from 5.5% in Central Europe to 8.6% in Ireland and UK (data not shown).
Moreover, five-year RS decreased with advancing age, from 89.5% for patients aged 15-44 years, to 85.4% in the age group 45-54 years, 83.6% for 55-64 years, 80.0% for 65-74 years and 72% for 75+ years old.
As regards morphology, the highest survival was observed in Europe for lentigo malignant (98.4%, range 97.2%-99.7%), followed by SSM (94.7%; 92.8%-95.0%), SM NOS (78.2%; 60.8%-82.7%), other SM (76.5%; 70.5%-80.4%) and then nodular (70.0%; 63.8%-70.1%) (Figure 2a ).
Among specified morphologies, the 5-year RS for nodular and other SM in Eastern Europe was worse than the European average. Women had better survival for all morphologies (Figures 2b-c) .
Five-year RS estimates for skin sub-sites in Europe were: 84.9% for limbs (95% CI 73.8%-85.4%), 80.6% for trunk (95% CI 73.8%-81.2%), 80.3% for head and neck (95% CI 73.8%-81.4%), and 64.9% for overlapping and unspecified sites (95% CI 63.9%-66.0%). Eastern Europe showed worse survival for all sub-sites ( Figure 3a ). However, we found that survival was generally better for women than for men for all sub-sites (Figures 3b-c). 
Discussion
The present study provided survival estimates based on the widest SM dataset ever published in the EUROCARE project.
Five-year RS for SM in Europe was high, 83.2%. Among the analyzed European regions, the best survival was found in Northern and Central Europe, then in Ireland and UK and in Southern Europe; Eastern Europe had the lowest survival. Areas with the best survival had the lowest intercountry variability while Eastern Europe presented the highest variability.
These findings confirmed previously documented geographical differences [16] .
SM survival is strongly related to the stage (Breslow thickness) at diagnosis [7] . Thinner SM have a better prognosis than thicker ones. Therefore, part of the geographical differences may be caused by different stage distribution at diagnosis. Early detection and population awareness on skin selfexamination promote the detection of thinner SM.
Unfortunately, information of stage is not available in the present study. However, a poorer distribution for Breslow's thickness has been already document in Eastern countries in comparison with Northern and Western countries [17] . Moreover, the 1-year RS was lower in Eastern Europe than in other regions, which indicated a larger proportion of SM with late stage at diagnosis [18] .
The close relationship between Breslow's thickness and prognosis legitimized those who support early diagnosis [19] [20] . However, a favourable survival does not necessarily indicate low mortality.
There is little evidence about the effectiveness of SM screening on mortality [21] [22] [23] [24] and no results from randomized trials evaluating mortality reduction are to be expected [22, 25] .
Despite the few indications for positive screening effectiveness from observational studies, an improvement in survival may be at least partially apparent due to a side effect of early diagnosis named overdiagnosis [8, 26] . This means the detection of tumours that for their nature (indolent, regression, etc.) or for the combination of their nature and the age of the patient would have not become clinically evident during the life of the patient [27] . The strong relationship between the increase in biopsy rate and the incidence of SM has been proposed as a clue for overdiagnosis [28] and, although at least part of the growth in incidence is true [29] -considering also the increase in mortality [2, 4] -overdiagnosis is contemplated as the main explanation for the rise in trends [30] . Therefore, differences in early diagnosis patterns could explain some of the variability in SM survival in Europe. The strong correlation evidenced between SM incidence and survival supports this hypothesis.
Other explanations could contribute to the differences in survival, such as different socioeconomic status, which has been shown to be an independent prognostic factor [31] . In addition, also treatment differences could be involved. For example, differential use of new expensive drugs could become more important for SM diagnosed in more recent years, due to the availability of BRAF or MEK inhibitors and anti-CTLA4 monoclonal antibodies [32] .
We also found a relationship between survival and SM morphology (worse survival for nodular SM and for NOS SM in Eastern Europe) and topography (worse survival for NOS and overlapping sites). Interpretation of SM with NOS morphology or site is difficult. As regards morphology, our data showed, in all the countries out of Eastern Europe, intermediate survival for NOS SM.
Therefore, in these regions NOS seemed to represent a 'sample' of all the morphology types. On the contrary, in Eastern Europe, morphology NOS had the worst prognosis. In this case NOS seemed to be a proof for cases selection, e.g. patients with advanced stage at diagnosis or older ones, etc.
In all the analysed regions survival for SM with NOS site was worse than for specified sites.
Moreover, a geographical variation in the case-mix by morphology sub-groups could contribute to explain at least some of the geographical differences observed in survival. However, survival in Eastern Europe for nodular, other types and NOS SM, was lower than the European average suggesting again the role of stage at diagnosis (possibly mediated by socioeconomic status, or treatment differences).
Sex has been confirmed [33] to be a strong survival predictor with better prognosis for women. The difference in relative survival between women and men was already present within the 1-year after diagnosis and increased over time. Women had better survival across all ages, skin sub-sites and morphologies. A better stage distribution at diagnosis has been suggested as a possible explanation [31] due to the supposed greater attention of women than men to their body and health. Moreover, an independent effect of female sex, supporting yet unknown biological factors, has also been suggested [34] .
The present study confirmed that SM RS decreased with increasing age of the patients. Also the effect of age was presumably mediated by thickness at diagnosis [35] as a different amount of early diagnosis across generations.
Five-year RS has improved over time, in all the areas and especially in Eastern countries. The survival levels in Northern and Central Europe were probably approaching a plateau considering the slowing down of the improvement during the last period of time.
The EUROCARE standardized protocol reassured about the quality and comparability of analyzed data [36] . The quality of the database has been addressed in another chapter of this monograph [10] .
However, although it is straightforward to interpret clearly an indicator of low quality, e.g. high proportion of patients lost to follow-up, it is more difficult to understand very high values of a quality index, e.g. 0% DCO or 100% microscopy verification. Also to infer the quality of histology reporting on the basis of the details in morphological entities definition may be fallacious; this could be the case of Denmark for which no detailed morphology codes have been made available for this study [35] .
Due to increased incidence and higher survival, the number of people with a history of SM has risen in the European populations. In 2010, more than 1,000,000 European citizens were estimated to have had a previous SM diagnosis [37] . The increase in incidence and the improvement in survival will boost the number of prevalent SM patients in all the European countries.
In conclusion, the heterogeneity in SM survival in Europe shows the need for the improvement in diagnostic activity in the Eastern countries, which all (except for Bulgaria) also have SM mortality rates higher than the European average [2] . The range of theoretical improvement is wide, in fact, there are more than 13 percentage points of differences in 5-year RS from Eastern to Northern or Central European Countries. Skin melanoma control and prevention should consider the possible overdiagnosis evaluating the improvement in survival together with those in mortality and incidence [38] . Moreover, primary prevention should match secondary prevention programs. 
